Spatial biology
6709 Spatially defining the future of cancer biology with advanced multiplexed immunofluorescence
shape Monitor
webinar
Troy Bloom

Senior Field Application Scientist, Ultivue

Spatially defining the future of cancer biology with advanced multiplexed immunofluorescence

30 minutes

Relevant for

InSituPlex

Description Immunotherapy has transformed the treatment of metastatic and recurrent solid tumors. Advances in technology in the past few years have created unprecedented opportunities to identify biomarkers of disease processes, especially by using multi-omics technologies and datasets to derive valid and useful signatures of disease. Despite these advances, today only a minority of patients respond to immunotherapies. Prediction of response to therapies such as checkpoint inhibitors that rely on activation of endogenous immune responses has been shown to be especially difficult due to complex and heterogeneous immune escape mechanisms in each patient. Increasing evidence suggests that measurement of robust biomarkers through spatial analysis of the tissue will be key to enable rational patient selection for an improved clinical trial process and design precise combination therapies. The urgency to discover and implement new biomarkers lays bare the need to integrate a variety of advanced tools to probe the dynamic nature of events happening in the tumor microenvironment (TME). Recently, technology updates integrating the use of multiplex immunohistochemistry/immunofluorescence (mIHC/IF) provides much needed insight into cellular composition, cellular functions, and cell-cell interactions. Importantly, recent studies have used mIHC/IF to explore specific immune cells as part of the tumor immune microenvironment (TME) and found that it is helpful for clinical prognosis and efficacy prediction in patients with cancer. In this presentation we will show a streamlined unique workflow supporting whole slide imaging of an 8-plex mIF and traditional same slide H&E fusion on a single tissue slide for a comprehensive tissue immunophenotyping analysis.

Learning Objectives

The utility of a high throughput, high-plex (Immuno-8) staining and mIF assay development for scientists and clinicians

Demonstrate how advanced AI-driven image analysis can be applied to discover cell types, populations and morphological context

Discuss how whole slide image analysis of the tumor microenvironment can provide insight into specific cancer types

Meet the host

Troy is an experienced analytical histotechnologist with expertise in histology, immunohistochemistry, in situ hybridization, digital slide scanning and image analysis within the GLP/GCP and pre-clinical environments along with a strong multidisciplinary CDx and research experience in models of oncology and autoimmune diseases.

Author
Troy Bloom
Senior Field Application Scientist, Ultivue
Categories: 6108 Informing Spatial Biology with Multiplexed Immunofluorescence: A Pathologist’s Perspective
shape Monitor
webinar
Sotirios Lakis MD, PhD

Sr. Director Molecular & Computational Pathology, Ultivue

Informing Spatial Biology with Multiplexed Immunofluorescence: A Pathologist’s Perspective

60 minutes

Relevant for

InSituPlex

Description Immunotherapy has transformed the treatment of metastatic and recurrent solid tumors but is challenged in that only a minority of patients respond, especially those therapies that rely on immune activation such as checkpoint inhibitors due to the complex and heterogeneous immune escape mechanisms which can develop in each patient. Therefore, the development of robust biomarkers, enabling rational patient selection and the design of precise combination therapies, is key for the continued success and improvement afforded by this valuable treatment. Overview of what is addressed: Why spatial relationships are important in tumor biology. Examine specific cell clustering, dispersion, and co-localization. To better understand the biology within tissues with a quantitative summary of the regions and phenotypes present.

Webinar Learning Objectives

Enable a better understanding of tumor heterogeneity, its immune environment and contextual relationship using spatial quantification of different immune and tumor cells.

Overview of Spatial Phenomics: Enabling the interrogation of complex cellular phenotypes, functional states, and intercellular relationships with the help of computational biology/pathology methods.

Opportunities and challenges for spatial biology and OMICs applications.

Meet the hosts

As a Senior Director, Molecular and Computational Pathology at UV I am responsible for establishing augmented pathology workflows and for implementing innovative data-driven QC methods. I am a board-certified MD, PhD anatomical pathologist with 10 years of experience in Translational Research, and Cancer Diagnostics.

I am passionate about building cross-disciplinary bridges to deliver innovative services and products while considering the applicable regulatory requirements. I am excited about new ways that molecular and spatial biomarkers can accelerate pharmaceutical research and improve the lives of patients.

Author
Sotirios Lakis MD, PhD

Sr. Director Molecular & Computational Pathology, Ultivue

Categories: 6078 Living in a Spatial World: Characterizing the Immune Environment in Tumors
shape Monitor
webinar
Angela Vasaturo, PhD; Lorcan Sherry, PhD

Associate Director Scientific Affairs, Ultivue; Chief Science Officer, OracleBio

Living in a Spatial World: Characterizing the Immune Environment in Tumors

77 minutes

Relevant for

InSituPlex

Description Immunotherapy has transformed the treatment of metastatic and recurrent solid tumors but is challenged in that only a minority of patients respond, especially those therapies that rely on immune activation such as checkpoint inhibitors due to the complex and heterogeneous immune escape mechanisms which can develop in each patient. Therefore, the development of robust biomarkers, enabling rational patient selection and the design of precise combination therapies, is key for the continued success and improvement afforded by this valuable treatment. Overview of what is addressed: Why spatial relationships are important in tumor biology. Examine specific cell clustering, dispersion, and co-localization. To better understand the biology within tissues with a quantitative summary of the regions and phenotypes present.

Webinar Learning Objectives

Enable a better understanding of tumor heterogeneity, its immune environment and contextual relationship using spatial quantification of different immune and tumor cells.

Overview of Spatial Phenomics: Enabling the interrogation of complex cellular phenotypes, functional states, and intercellular relationships with the help of computational biology/pathology methods.

Opportunities and challenges for spatial biology and OMICs applications.

Meet the hosts

As a Senior Director, Molecular and Computational Pathology at UV I am responsible for establishing augmented pathology workflows and for implementing innovative data-driven QC methods. I am a board-certified MD, PhD anatomical pathologist with 10 years of experience in Translational Research, and Cancer Diagnostics.

I am passionate about building cross-disciplinary bridges to deliver innovative services and products while considering the applicable regulatory requirements. I am excited about new ways that molecular and spatial biomarkers can accelerate pharmaceutical research and improve the lives of patients.

Author
Sotirios Lakis MD, PhD

Sr. Director Molecular & Computational Pathology, Ultivue

Lorcan is an image analysis expert who previously spent 10 years in the pharmaceutical industry as a group leader (Organon, Schering-Plough, Merck & Co.). He led a group responsible for performing histology, immunohistochemistry / image analysis and he has considerable experience in developing translational biomarker strategies for projects across various therapeutic areas. He is a Prince 2® qualified project manager and has extensive experience in study management.

Author
Lorcan Sherry, PhD

Chief Science Officer, OracleBio

Categories: 5903 Development of specific multiplexed immunofluorescence immune assays to study mouse models of tumorigenesis
shape book
ebook

Development of specific multiplexed immunofluorescence immune assays to study mouse models of tumorigenesis

Register here for download

Relevant for

Collaboration, FixVUE, InSituPlex

Description Developing a multiplex immunofluorescence assay for the in depth characterization of activatedT cells in tumor tissue samples.

Want to meet with us? Check out our upcoming events.

Want to meet with us? Check out our upcoming events.

Categories: 6083 Importance of Spatial Distribution Insight from Clinical Biopsies
shape Monitor
webinar
Jay Lee, MD, PhD

Director of R&D and Innovation, Ultivue

Importance of Spatial Distribution Insight from Clinical Biopsies

55 minutes

Relevant for

InSituPlex

Description Immunotherapy has transformed the treatment of metastatic and recurrent solid tumors but is challenged in that only a minority of patients respond, especially those therapies that rely on immune activation such as checkpoint inhibitors due to the complex and heterogeneous immune escape mechanisms which can develop in each patient. Therefore, the development of robust biomarkers, enabling rational patient selection and the design of precise combination therapies, is key for the continued success and improvement afforded by this valuable treatment. Overview of what is addressed: Why spatial relationships are important in tumor biology. Examine specific cell clustering, dispersion, and co-localization. To better understand the biology within tissues with a quantitative summary of the regions and phenotypes present.

Webinar Learning Objectives

Enable a better understanding of tumor heterogeneity, its immune environment and contextual relationship using spatial quantification of different immune and tumor cells.

Overview of Spatial Phenomics: Enabling the interrogation of complex cellular phenotypes, functional states, and intercellular relationships with the help of computational biology/pathology methods.

Opportunities and challenges for spatial biology and OMICs applications.

Meet the hosts

As a Senior Director, Molecular and Computational Pathology at UV I am responsible for establishing augmented pathology workflows and for implementing innovative data-driven QC methods. I am a board-certified MD, PhD anatomical pathologist with 10 years of experience in Translational Research, and Cancer Diagnostics.

I am passionate about building cross-disciplinary bridges to deliver innovative services and products while considering the applicable regulatory requirements. I am excited about new ways that molecular and spatial biomarkers can accelerate pharmaceutical research and improve the lives of patients.

Author
Sotirios Lakis MD, PhD

Sr. Director Molecular & Computational Pathology, Ultivue

Categories: 6085 Improving Immuno-Oncology Research Using Spatial Phenomics
shape Monitor
webinar
Keith Wharton, MD, PhD, FCAP

Vice President, Medical Director, Ultivue

Improving Immuno-Oncology Research Using Spatial Phenomics

46 minutes

Relevant for

InSituPlex

Description Immunotherapy has transformed the treatment of metastatic and recurrent solid tumors but is challenged in that only a minority of patients respond, especially those therapies that rely on immune activation such as checkpoint inhibitors due to the complex and heterogeneous immune escape mechanisms which can develop in each patient. Therefore, the development of robust biomarkers, enabling rational patient selection and the design of precise combination therapies, is key for the continued success and improvement afforded by this valuable treatment. Overview of what is addressed: Why spatial relationships are important in tumor biology. Examine specific cell clustering, dispersion, and co-localization. To better understand the biology within tissues with a quantitative summary of the regions and phenotypes present.

Meet the hosts

As a Senior Director, Molecular and Computational Pathology at UV I am responsible for establishing augmented pathology workflows and for implementing innovative data-driven QC methods. I am a board-certified MD, PhD anatomical pathologist with 10 years of experience in Translational Research, and Cancer Diagnostics.

I am passionate about building cross-disciplinary bridges to deliver innovative services and products while considering the applicable regulatory requirements. I am excited about new ways that molecular and spatial biomarkers can accelerate pharmaceutical research and improve the lives of patients.

Author
Sotirios Lakis MD, PhD

Sr. Director Molecular & Computational Pathology, Ultivue

Categories: 5869 Analysis of macrophages to the overall PD-L1 microenvironment using TMAs and InSituPlex
shape poster
poster

Presented at: ASCO 2022

Analysis of macrophages to the overall PD-L1 microenvironment using TMAs and InSituPlex

Register here for download

Relevant for

Collaboration, FixVUE, InSituPlex

Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.

Authors

Marie Cumberbatch, Douglas Wood, Gourab Chatterjee, Christopher Womack, Milan Bhagat, Lorcan Sherry

Want to meet with us? Check out our upcoming events.

Want to meet with us? Check out our upcoming events.

Categories: 5816 Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer
shape Monitor
webinar
Jennifer Giltnane MD, PhD

Principal Pathologist-Scientist, Genentech

Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer

Length: 46 minutes

Relevant for

FixVUE, InSituPlex

Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.

Webinar Learning Objectives

A better understanding of tumor heterogeneity, its immune environment and contextual relationship requires the spatial quantification of different immune and tumor cells along with the genetic background of the individual cancer.

The utilization of scRNA-seq and multiplexed Immunofluorescence techniques on NSCLC tumors to identify three main populations of intratumoral B and plasma cells.

An overview on the availability of digital tools in histopathology to allow interpreting the high-dimensional complexity of the spatial and immunological heterogeneity in tissue and integrating big (molecular) data to select the best and most effective treatment including combination and advanced therapies.

Meet the host

Jena Giltnane is a translational pathologist-scientist in Genentech’s division of research and early development, where she leads digital and spatial pathology in support of translational oncology and cancer immunology programs through the use of multiplexed immunofluorescence tissue assays, tissue technology evaluation, and the collaborative development of deep learning based image analysis models in digital pathology.

Dr. Giltnane completed her MD, PhD, at Yale University in the laboratory of Dr. David Rimm and postdoctoral training in the laboratory of Dr. Carlos Arteaga at Vanderbilt University, where she also completed her Residency in Anatomic and Clinical Pathology.

She is an expert in genomic and proteomic biomarkers of diagnosis, prediction, and prognosis in breast cancer and the curation and analysis of high-dimensional clinical data.

Author
Jennifer Giltnane MD, PhD

Principal Pathologist-Scientist, Genentech

Want to meet with us? Check out our upcoming events.

Want to meet with us? Check out our upcoming events.

Categories: 5848 Spatial multi-omics analysis targeting protein and RNA biomarkers on a single FFPE tissue section using an integrated staining and imaging workflow
shape poster
poster

Presented at: ASCO 2022

Spatial multi-omics analysis targeting protein and RNA biomarkers on a single FFPE tissue section using an integrated staining and imaging workflow

Register here for download

Relevant for

FixVUE, InSituPlex, RNA scope

Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.

Authors

Marie Cumberbatch, Douglas Wood, Gourab Chatterjee, Christopher Womack, Milan Bhagat, Lorcan Sherry

Want to meet with us? Check out our upcoming events.

Want to meet with us? Check out our upcoming events.

Categories: 5847 Development of specific multiplexed immunofluorescence immune assays to study mouse models of tumorigenesis
shape poster
poster

Presented at: ASCO 2022

Development of specific multiplexed immunofluorescence immune assays to study mouse models of tumorigenesis

Register here for download

Relevant for

FixVUE, InSituPlex

Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.

Authors

Marie Cumberbatch, Douglas Wood, Gourab Chatterjee, Christopher Womack, Milan Bhagat, Lorcan Sherry

Want to meet with us? Check out our upcoming events.

Want to meet with us? Check out our upcoming events.

Categories: 5828 High throughput tissue phenotyping and imaging of the tumor immune microenvironment using novel FlexVUE™multiplexed immunofluorescence assays
shape poster
poster

Presented at: ASCO 2022

High throughput tissue phenotyping and imaging of the tumor immune microenvironment using novel FlexVUE™multiplexed immunofluorescence assays

Register here for download

Relevant for

FlexVUE, InSituPlex

Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.

Authors

Marie Cumberbatch, Douglas Wood, Gourab Chatterjee, Christopher Womack, Milan Bhagat, Lorcan Sherry

Want to meet with us? Check out our upcoming events.

Want to meet with us? Check out our upcoming events.

Categories: 5829 Improved Understanding of the Biology and Pathophysiology of the TME in PDAC Samples Revealed by Both InSituPlex and Imaging Mass Cytometry
shape poster
poster

Presented at: ASCO 2022

Improved Understanding of the Biology and Pathophysiology of the TME in PDAC Samples Revealed by Both InSituPlex and Imaging Mass Cytometry

Register here for download

Relevant for

Collaboration, FixVUE, Imaging mass cytometry, InSituPlex

Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.

Authors

Marie Cumberbatch, Douglas Wood, Gourab Chatterjee, Christopher Womack, Milan Bhagat, Lorcan Sherry

Want to meet with us? Check out our upcoming events.

Want to meet with us? Check out our upcoming events.

Categories: 5814 The power of data analytics in biomarker programs
shape Monitor
webinar
Moritz Widmaier, PhD

Senior Product Manager AI & Data Analytics

The power of data analytics in biomarker programs

Length: 10 minutes

Relevant for

FixVUE, InSituPlex

Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.

Meet the host

Jena Giltnane is a translational pathologist-scientist in Genentech’s division of research and early development, where she leads digital and spatial pathology in support of translational oncology and cancer immunology programs through the use of multiplexed immunofluorescence tissue assays, tissue technology evaluation, and the collaborative development of deep learning based image analysis models in digital pathology.

Dr. Giltnane completed her MD, PhD, at Yale University in the laboratory of Dr. David Rimm and postdoctoral training in the laboratory of Dr. Carlos Arteaga at Vanderbilt University, where she also completed her Residency in Anatomic and Clinical Pathology.

She is an expert in genomic and proteomic biomarkers of diagnosis, prediction, and prognosis in breast cancer and the curation and analysis of high-dimensional clinical data.

Author
Jennifer Giltnane MD, PhD

Principal Pathologist-Scientist, Genentech

Want to meet with us? Check out our upcoming events.

Want to meet with us? Check out our upcoming events.

Categories: 5796 Introduction to Ultivue’s capabilities for immuno-oncology biomarker programs
shape Monitor
webinar
Moritz Widmaier, PhD; Branden Hopkinson, PhD

Senior Product Manager AI & Data Analytics

Introduction to Ultivue’s capabilities for immuno-oncology biomarker programs

Length: 20 minutes

Relevant for

FlexVUE, InSituPlex

Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.

Meet the hosts

Moritz will drill his way through whatever intellectual challenge you’ll put in front of him. He previously perforated biochemistry, image analysis, data science, immuno-oncology biomarkers, product management/ownership. He’ll condense the best of our ideas into a coherent roadmap. His product backlog will guide us towards our vision one step at a time.

Author
Moritz Widmaier, PhD

Senior Product Manager AI & Data Analytics

Meet the host

Jena Giltnane is a translational pathologist-scientist in Genentech’s division of research and early development, where she leads digital and spatial pathology in support of translational oncology and cancer immunology programs through the use of multiplexed immunofluorescence tissue assays, tissue technology evaluation, and the collaborative development of deep learning based image analysis models in digital pathology.

Dr. Giltnane completed her MD, PhD, at Yale University in the laboratory of Dr. David Rimm and postdoctoral training in the laboratory of Dr. Carlos Arteaga at Vanderbilt University, where she also completed her Residency in Anatomic and Clinical Pathology.

She is an expert in genomic and proteomic biomarkers of diagnosis, prediction, and prognosis in breast cancer and the curation and analysis of high-dimensional clinical data.

Author
Jennifer Giltnane MD, PhD

Principal Pathologist-Scientist, Genentech

Want to meet with us? Check out our upcoming events.

Want to meet with us? Check out our upcoming events.

Categories: 5782 FlexVUE case studies
shape Monitor
webinar
Kirsteen MacClean, PhD

Senior Director Scientific Brand Strategy

FlexVUE case studies

Length: 20 minutes

Relevant for

FlexVUE, InSituPlex

Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.

Meet the host

Jena Giltnane is a translational pathologist-scientist in Genentech’s division of research and early development, where she leads digital and spatial pathology in support of translational oncology and cancer immunology programs through the use of multiplexed immunofluorescence tissue assays, tissue technology evaluation, and the collaborative development of deep learning based image analysis models in digital pathology.

Dr. Giltnane completed her MD, PhD, at Yale University in the laboratory of Dr. David Rimm and postdoctoral training in the laboratory of Dr. Carlos Arteaga at Vanderbilt University, where she also completed her Residency in Anatomic and Clinical Pathology.

She is an expert in genomic and proteomic biomarkers of diagnosis, prediction, and prognosis in breast cancer and the curation and analysis of high-dimensional clinical data.

Author
Jennifer Giltnane MD, PhD

Principal Pathologist-Scientist, Genentech

Want to meet with us? Check out our upcoming events.

Want to meet with us? Check out our upcoming events.

Categories: